Qlucore (QCORE) Q4 2026 earnings summary

Executive summary

• Launched new AI-based Qlucore Insights tests for Acute Myeloid Leukemia and Bladder Cancer for research use, marking milestones in the EU-funded project.

• Net sales declined 34% year-over-year to SEK 6,737k, with a 44% drop in Q4 sales compared to the same quarter last year.

• Cost reduction measures, including staff reductions and consulting cuts, were implemented to address declining sales; full impact expected by August 2026.

• Majority of sales derived from Qlucore Omics Explorer, but sales impacted by increased competition from free solutions and reduced research funding.

• Liquidity to be strengthened by an upcoming EU grant payment of over SEK 5 million.

Financial highlights

• Net sales for the year: SEK 6,737k (down from SEK 10,208k year-over-year).

• Adjusted EBITDA for the year: SEK -12,873k (improved from SEK -24,116k year-over-year).

• Net result for the year: SEK -36,523k (down from SEK -20,535k year-over-year).

• Cash flow from operating activities: SEK -12,464k (improved from SEK -14,154k year-over-year).

• Net cash flow: SEK -2,343k (improved from SEK -23,560k year-over-year); cash and cash equivalents at period end: SEK 2,969k.

• Equity at period end: SEK 36,305k (down from SEK 58,465k year-over-year).

Outlook and guidance

• No market outlook or business performance forecasts are provided.

• Full effect of cost reductions expected by August 2026.